{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:50:11Z","timestamp":1791525011577,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["3UM1AI148373-01S1"],"award-info":[{"award-number":["3UM1AI148373-01S1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jim.2026.114127","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:09:20Z","timestamp":1790546960000},"page":"114127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Qualification of ELISA and PRNT methodologies to measure RSV humoral immunity using human clinical samples"],"prefix":"10.1016","volume":"551","author":[{"given":"Matthew H.","family":"Harband","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Pecor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan J.","family":"Berube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Smytheman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha E.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2026.114127_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1624007","article-title":"Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia","volume":"16","author":"Alandijany","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jim.2026.114127_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/v13071214","article-title":"Functional features of the respiratory syncytial virus G protein","volume":"13","author":"Anderson","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jim.2026.114127_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/v13020352","article-title":"Respiratory syncytial virus (RSV) G protein vaccines with central conserved domain mutations induce CX3C-CX3CR1 blocking antibodies","volume":"13","author":"Bergeron","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jim.2026.114127_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1283120","article-title":"Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection","volume":"14","author":"Brady","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jim.2026.114127_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf695.909","article-title":"P-696. Rapid estimates of RSV disease burden in the United States","volume":"13","author":"Carter","year":"2026","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.jim.2026.114127_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41541-018-0057-5","article-title":"The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial","volume":"3","author":"Coler","year":"2018","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jim.2026.114127_bb0035","article-title":"Safety and immunogenicity of the adjunct therapeutic vaccine ID93+GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial","author":"Day","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.jim.2026.114127_bb0040","series-title":"Guidance for industry bioanalytical methods validation","author":"Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.jim.2026.114127_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2026.128222","article-title":"The evolving landscape of RSV immunization: current policies and practices across Europe","volume":"76","author":"Franck","year":"2026","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2026.114127_bb0050","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.201412-2256OC","article-title":"Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus","volume":"191","author":"Habibi","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jim.2026.114127_bb0055","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.iac.2019.03.005","article-title":"Infant immune response to respiratory viral infections","volume":"39","author":"Heinonen","year":"2019","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.jim.2026.114127_bb0060","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/19420862.2018.1433974","article-title":"Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo","volume":"10","author":"Jacobino","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.jim.2026.114127_bb0065","article-title":"Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation","volume":"15","author":"Kaler","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jim.2026.114127_bb0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0166-0934(01)00316-0","article-title":"Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays","volume":"96","author":"LaBarre","year":"2001","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jim.2026.114127_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2021.113160","article-title":"Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples","volume":"499","author":"Larsen","year":"2021","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2026.114127_bb0080","doi-asserted-by":"crossref","first-page":"10776","DOI":"10.1128\/JVI.76.21.10776-10784.2002","article-title":"The major phosphorylation sites of the respiratory syncytial virus phosphoprotein are dispensable for virus replication in vitro","volume":"76","author":"Lu","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.jim.2026.114127_bb0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.17145\/jab.18.010","article-title":"Bioanalytical method development and validation: from the USFDA 2001 to the USFDA 2018 guidance for industry","volume":"4","author":"Meesters","year":"2018","journal-title":"J. Appl. Bioanal."},{"key":"10.1016\/j.jim.2026.114127_bb0090","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s40121-024-01012-2","article-title":"Differences between RSV a and RSV B subgroups and implications for pharmaceutical preventive measures","volume":"13","author":"Nuttens","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.jim.2026.114127_bb0095","article-title":"Challenges and limitations of current RSV prevention strategies in infants and young children: a narrative review","volume":"13","author":"Principi","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jim.2026.114127_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126936","article-title":"Binding and neutralising antibodies to respiratory syncytial virus and influenza a virus in serum and bronchoalveolar lavage fluid of healthy adults in the United States: a cross-sectional study","volume":"53","author":"Raja","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2026.114127_bb0105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1128\/CMR.00090-16","article-title":"The human immune response to respiratory syncytial virus infection","volume":"30","author":"Russell","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jim.2026.114127_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2576","article-title":"Systematic review of the efficacy and safety of RSV-specific monoclonal antibodies and antivirals in development","volume":"34","author":"Sevendal","year":"2024","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.jim.2026.114127_bb0115","doi-asserted-by":"crossref","first-page":"e4400","DOI":"10.1093\/cid\/ciaa951","article-title":"Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants","volume":"73","author":"Sim\u00f5es","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jim.2026.114127_bb0120","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1080\/21645515.2019.1688040","article-title":"Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season","volume":"16","author":"Van Der Plas","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jim.2026.114127_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/v14020419","article-title":"How RSV proteins join forces to overcome the host innate immune response","volume":"14","author":"Van Royen","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jim.2026.114127_bb0130","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41541-024-01059-9","article-title":"DS2 designer pre-fusion F vaccine induces strong and protective antibody response against RSV infection","volume":"9","author":"Yang","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jim.2026.114127_bb0135","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/infdis\/jiq100","article-title":"Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and\/or motavizumab","volume":"203","author":"Zhu","year":"2011","journal-title":"J. Infect. Dis."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175926001031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175926001031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:05:53Z","timestamp":1791522353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175926001031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":27,"alternative-id":["S0022175926001031"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2026.114127","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Qualification of ELISA and PRNT methodologies to measure RSV humoral immunity using human clinical samples","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2026.114127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114127"}}